All News

podcast logo

RheumNow Podcast – Function Follows Form (10.2.20)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Regulatory approvals, update on global rheumatology alliance, smoking and psoriasis, gabapentin let down and defining difficult RA.

Read Article
cell3.jpg

CXCR3 and Restricted T Cells in Psoriatic Arthritis Inflammation

Jack Cush, MD

Research from Oxford University suggests a potential pathogenic role for the chemokine CXCR3 and clonally restricted CD8+ T cells in the pathogenesis of psoriatic arthritis (PsA) based studies of PsA synovial fluid samples obtained by arthrocentesis from 11 patients with large-joint oligo Ps

Read Article
pregnancy.pills_.jpg

ACR 2020 Reproductive Guidelines - Medication Use with Pregnancy

Jack Cush, MD

The American College of Rheumatology (ACR) has published guidelines to manage reproductive health issues in rheumatic disease (RMD) patients before, during and after pregnancy.

Read Article
podcast logo

RheumNow Podcast – Rheum Lives Matter (8.28.20)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week. Of mice and men in cartilage, the efficacy of JAK inhibitors in patients who are having skin problems, nrAxSpa has its own diagnostic code, metformin, talking about Back Talk, plus so much more.

Read Article
sperm.fertilization.preg_.jpg

Filgotinib Decision Delayed by FDA

Jack Cush, MD

On August 18th, Gilead and Galapagos received a complete response letter from the FDA, which will delay consideration of filgotinib for the treatment of moderate-to-severe RA.

Read Article
podcast logo

RheumNow Podcast - The SARS-CoV-2 Update (8-14-20)

Jack Cush, MD

Dr. Jack Cush updates the news and journal articles from the past week on RheumNow.com, with information on enthesitis, nr-Ax-SpA, UAB, Blockbuster Rheum Drugs and use of ACE inhibitors.

Read Article
COVID infection mask

Rheumatic Diseases, Drugs and COVID-19 Guidelines

Jack Cush, MD

Several recent publications have focused on the risk and outcomes of rheumatic disease (RDD) and autoimmune patients who become infected with SARs-CoV-2.

Read Article
LBP.red_.jpg

Secukinumab Effective in Non-Radiographic Axial SpA

Jack Cush, MD

The PREVENT trial was a one year, phase III study that showed significant benefits when secukinumab (SEC) was given to patients with active non‐radiographic axial spondyloarthritis (nr‐axSpA) for 52 weeks.

Read Article
podcast logo

RheumNow Podcast - Top 13 Rheumatology Centers (7-31-20)

Jack Cush, MD

Dr. Jack Cush reviews the news and TOP 13 list of Best Rheumatology Hospitals.

Read Article
podcast logo

RheumNow Podcast – COVID-19 Responds to Steroids (7.24.20)

Jack Cush, MD

Dr. Jack Cush reviews the News and Journal Reports from the past week on RheumNow.com.

Read Article
Swiss cohort of 666 axSpA, RA & PsA pts seen before, during & after COVID; consults dropped 52%, remote visits increased 129%, & non-compliance slightly increased during COVID (axSpA 20% vs 13% before, p=0.003); but no incr in flares(<15%) or Dz activity https://t.co/lWb7WCwGbN

Links:

Dr. John Cush RheumNow ( View Tweet)

ASSERT looked at ankylosing spondylitis (AS) pts treated with infliximab (n = 16) or placebo (n = 7). Infliximab was shown to reduce depression & depressive symptoms by improving AS disease Sxs. There was no link between CRP inflammation & depression https://t.co/oC5rQP2Jec

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of early axSpA from the DESIR cohort looked at MRIs of the SI joint/spine @baseline, 2 & 5 yrs; showed that bone marrow edema pn MRI‐SIJ and ‐spine at baseline predicted of ‐year damage pm MRI‐SIJ [OR=4.2] and MRI‐spine [OR=10.7] https://t.co/3PAJ5Zt4Pp

Links:

Dr. John Cush RheumNow ( View Tweet)

Systematic literature review of the incidence of SpA subtypes: psoriatic arthritis overall IR of 9.7 per 100.000 PYs; AS overall IR of 4.8/100kPY, and reactive arthritis overall IR estimate of 3.4/100KPY. Little on undifferentiated spondyloarthritis https://t.co/U8yqk30cWb

Links:

Dr. John Cush RheumNow ( View Tweet)

Non-Radiographic Axial Spondyloarthritis has Its Own Diagnostic Code; As of October 2020, nr-axSpA will be officially included in the 10th version of the International Classification of Diseases (ICD-10) coding manual as M46.8 https://t.co/AftIecd2z3 https://t.co/973yJUW57p

Links:

Dr. John Cush RheumNow ( View Tweet)
AbbVie has submited Regulatory Application to FDA and EMA for upadacitinib proposed indication to treate active Ankylosing Spondylitis https://t.co/RPaOXCarEZ

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast - The SARS-CoV-2 Update (8-14-20) Dr. Jack Cush highlights the latest numbers on COVID-19 and its impact on Rheumatic Patients. Also, Top 4 best sellers, new take on NR-Ax-SpA & enthesitis https://t.co/IJAHGynSNd

Links:

Dr. John Cush RheumNow ( View Tweet)

The RheumNow Podcast is up: The SARS-CoV-2 Update with info on enthesitis, nr-Ax-SpA, UAB, Blockbuster Rheum Drugs and use of ACE inhibitors. Watch it here> https://t.co/1WUZQJajgW or podcast listen here>> https://t.co/IJAHGynSNd

Links:

Dr. John Cush RheumNow ( View Tweet)

Systematic literature finds a connection between ankylosing spondylitis (AS) and dementia (RR 1.19 [95% CI 1.01‐1.41]). From a total of 6562 articles reviewed, only 4 met criteria - analysis included 156418 pts. Cause? inflammation, inactivity?

Dr. John Cush RheumNow ( View Tweet)

Metanalysis of 10 studies ( p534 patients) shows that exercise in ankylosing spondylitis improves pain, function and disease activity. Statistically signif improvement in pain (P<0.0001), BASDAI (P <0.00001), and BASFI (P<0.00001), but not CRP and ESR. https://t.co/fKo9kNOrmO

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×